Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis

References

• Aflatoonian, A., Ghandi, S., & Tabibnejad, N. (2008). Comparison of coasting with Cabergoline administration for prevention of early severe OHSS in ART. Iranian Journal of Reproductive Medicine, 6, 51–55.
   Google Scholar
• Ahmadi, Sh., Rahmani, E., & Oskouian, H. (2010). Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome. Reproductive BioMedicine Online, 20, S41–S42.
   Google Scholar
• Alhalabi, M., Samawi, S., Taha, A., Kafri, N., Modi, S., Khatib, A., et al. (2011). Quinagolide reduces OHSS in high risk ICSI patients. Abstracts of the 27th Annual Meeting of European Society of Human Reproduction and Embryology, Stockholm, Sweden, 3–6 July 2011. Human Reproduction, 26, P–508. http://humrep.oxfordjournals.org/content/26/suppl_1/i296.full.pdf+html
   Google Scholar
• Alvarez, C., Alonso-Muriel, I., Garcia, G., Crespo, J., Bellver, J., Simon, C., & Pellicer, A. (2002). Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Human Reproduction, 22, 3210–3214.
   Google Scholar
• Alvarez, C., Martí-Bonmatí, L., Novella-Maestre, E., Sanz, R., Gomez, R., Fernandez-Sanchez, M., et al. (2007). Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism, 92, 2931–2937.
   PubMed Web of Science ®Google Scholar
• Ata, B., Seyhan, A., Orhaner, S., & Urman, B. (2009). High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertility and Sterility, 92, 1168.e1–4.
   PubMed Web of Science ®Google Scholar
• Busso, C., Fernandez-Sanchez, M., Garcia-Velasco, J.A., Landeras, J., Ballesteros, A., Munoz, E., et al. (2010). The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction, 25, 995–1004.
   PubMed Web of Science ®Google Scholar
• Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P.T., et al. (2008). Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive BioMedicine Online, 17, 751–755.
   PubMed Web of Science ®Google Scholar
• CEMACH. (2007). National Institute for Clinical Excellence, Scottish Executive Health Department, Department of Health, Social Services and Public Safety, Northern Ireland. Saving mother's lives; 2003–2005. The seventh report of the confidential enquiries into maternal deaths in the United Kingdom. London: CEMACH, 2007 [cited Available from http://www.cemach.org.uk/getattachment/26dae364-1fc9-4a29-a6cbafb3f251f8f7/Saving-Mothers%E2%80%99-Lives-2003-2005-(Fullreport).aspx. December 24.
   Google Scholar
• Ferraretti, A.P., Gianaroli, L., Diotallevi, L., Festi, C., & Trounson, A. (1992). Dopamine treatment for severe ovarian hyperstimulation syndrome. Human Reproduction, 7, 180–183.
   Google Scholar
• Gustofson, P.B.R. & Van Nest, K.S. (2005). Aggressive outpatient management of severe ovarian hyperstimulation syndrome avoids complications and prolonged disease course. Fertility and Sterility, 84, S95–S230.
   Google Scholar
• Hwang, J.L., Lin, Y.H., & Seow, K.M. (2010). Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels. International Journal of Gynaecology and Obstetrics, 108, 159–160.
   Google Scholar
• Kasum, M. (2010). New insights in mechanisms for development of ovarian hyperstimulation syndrome. Collegium Antropologicum, 34, 1139–1143.
   PubMedGoogle Scholar
• Manno, M., Tomei, F., Marchesan, E., & Adamo, V. (2005). Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?European Journal of Obstetrics, Gynecology, and Reproductive Biology, 122, 127–128.
   PubMed Web of Science ®Google Scholar
• Navot, D., Bergh, P.A., & Laufer, N. (1992). Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility, 58, 249–261.
   PubMed Web of Science ®Google Scholar
• Papaleo, E., Doldi, N., De Santis, L., Marelli, G., Marsiglio, E., Rofena, S., & Ferrari, A. (2001). Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Human Reproduction, 16, 2263–2266.
   PubMed Web of Science ®Google Scholar
• Ricci, E., Parazzini, F., Motta, T., Ferrari, CI., Colao, A., Clavenna A, et al. (2002). Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology, 16, 791–793.
   PubMed Web of Science ®Google Scholar
• Rizk, B. & Aboulghar, M. (1991). Modern management of ovarian hyperstimulation syndrome. Human Reproduction, 6, 1082–1087.
   PubMed Web of Science ®Google Scholar
• Robert, E., Musatti, L., Piscitelli, G., & Ferrari, C.I. (1996). Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reproductive Toxicology, 10, 333–337.
   PubMed Web of Science ®Google Scholar
• Rollene, N.L., Amols, M.H., Hudson, S.B.A., & Coddington, C.C. (2009). Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertility and Sterility, 92, 1169.e15–17.
   Google Scholar
• Salah Edeen, A.M.R., Alhelou, Y.M. (2009). Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Abstracts of the 25th Annual Meeting of ESHRE; 28 June–1 July; Amsterdam, The Netherlands.
   Google Scholar
• Shaltout, A., Shohayeb, A., Eid, M., & Abbas, S. (2009). Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, The Netherlands, 28 June–1 July 2009.Human Reproduction, 24, O–154. http://humrep.oxfordjournals.org/content/24/suppl_1/i60.full.pdf+html
   Google Scholar
• Sherwal, V., Malik, S., & Bhatia, V. (2010). Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. Journal of Human Reproductive Sciences, 3, 85–90.
   PubMedGoogle Scholar
• Shrivastav, P., Nadkarni, P., & Craft, I. (1994). Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Human Reproduction, 9, 812–814.
   PubMed Web of Science ®Google Scholar
• Soares, S.R. (2012). Etiology of OHSS and use of dopamine agonists. Fertility and Sterility,97, 517–522.
   PubMed Web of Science ®Google Scholar
• Sohrabvand, F., Ansaripour, S., Bagheri, M., Shariat, M., & Jafarabadi, M. (2009). Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility, 3, 35–40.
   Google Scholar
• Soliman, B.S. (2011). Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome. Middle East Fertility Society Journal, 16, 56–60.
   Google Scholar
• Spitzer, D., Wogatzky, J., Murtinger, M., Zech, M.H., Haidbauer, R., & Zech, N.H. (2011). Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 95, 2742–2744.e1.
   PubMed Web of Science ®Google Scholar
• Tang, H., Hunter, T., Hu, Y., Zhai, S.-D., Sheng, X., & Hart, R.J. (2012). Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2, CD008605.
   Google Scholar
• Tsunoda, T., Shibahara, H., Hirano, Y., Suzuki, T., Fujiwara, H., Takamizawa, S., et al. (2003). Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecological Endocrinology, 17, 281–286.
   PubMedGoogle Scholar
• van der Linden, M., Buckingham, K., Farquhar, C., Kremer, J.A., & Metwally, M. (2011). Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews, 10, CD009154. doi:10.1002/14651858.CD009154.pub2
   Google Scholar